-
Enlicitide
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Enlicitide 2407527-14-2 2027 [Indication]
1. Hypercholesterolemia: As an adjunct to diet and exercise, to reduce low-density lipoprotein cholesterol (LDL-C) in adult patients with hypercholesterolemia.
2. Heterozygous familial hypercholesterolemia (HeFH): For the treatment of adult patients with heterozygous familial hypercholesterolemia (HeFH).
-
Icotrokinra hydrochloride
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Icotrokinra hydrochloride 3049491-48-4 [Indication]
Moderate-to-severe plaque psoriasis: For the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.
-
Ubrogepant
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Ubrogepant 1374248-77-7 Dec, 2027 Sep.28, 2035 estimated PV Completion – Oct, 2027 [Indication]
For the acute treatment of migraine with or without aura in adults.
-
Remibrutinib
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Remibrutinib 1787294-07-8 Jun, 2028 Nov.13, 2034 estimated PV Completion - Mar, 2028 [Indication]
Chronic spontaneous urticaria (CSU): For the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment.
-
Laroprovstat
API’s Name CAS No. US DMF Patent Expiry Date( U.S) Current Status Laroprovstat 2455427-91-3 2027 Jan.23, 2040 [Indication]
1. Hypercholesterolemia: For the reduction of low-density lipoprotein cholesterol (LDL-C) in adult patients with hypercholesterolemia, as an adjunct to statin therapy.
2. Dyslipidemia: For the management of dyslipidemia in adult patients.
3. Cardiovascular Disease: For the reduction of cardiovascular risk in patients with atherosclerotic cardiovascular disease (ASCVD).
-
Daraxonrasib
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Daraxonrasib 2765081-21-6 Jun, 2028 Jan.24, 2042 estimated PV Completion – Mar, 2028 [Indication]
- For the treatment of patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
-
Brensocatib
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Brensocatib 2923839-30-7 Mar, 2027 Mar.12, 2035 estimated PV Completion – Dec, 2026 [Indication]
For the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older.
-
Atogepant
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Atogepant 1374248-81-3 Jun, 2027 Sep.28, 2035 estimated PV Completion – Apr, 2027 [Indication]
1. For the preventive treatment of episodic migraine in adults.
2. For the preventive treatment of chronic migraine in adults.
-
Asciminib
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Asciminib 2119669-71-3 Jul, 2027 May.13, 2033 estimated PV Completion – May, 2027 [Indication]
1. Patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) who have been previously treated with two or more tyrosine kinase inhibitors (TKIs).
2. Patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) who have the T315I mutation.
-
Iptacopan
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Iptacopan Hydrochloride 1646321-63-2 Feb, 2027 Jul.14, 2034 estimated PV Completion – Dec, 2026 Iptacopan Hydrochloride Monohydrate 2447007-60-3 Feb, 2027 May, 2041 estimated PV Completion – Dec, 2026 [Indication]
1. Paroxysmal nocturnal hemoglobinuria (PNH)：For the treatment of PNH in adult patients.
2. C3 glomerulopathy (C3G)：For the treatment of C3G in adult patients to reduce proteinuria.
3. Immunoglobulin A nephropathy (IgAN)：For the treatment of primary IgAN in adult patients with rapid progression risk to reduce proteinuria levels.
-
Suzetrigine
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Suzetrigine 2649467-58-1 Aug, 2026 Dec.4, 2040 estimated PV Completion – Aug, 2026 [Product]
Provide the API as well as the SDD (Spray Dried Dispersion).
[Indication]
For the management of acute pain of moderate to severe intensity in adults.
-
Orforglipron
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Orforglipron 2212020-52-3 Dec, 2026 Sep.26, 2037 estimated PV Completion – Sep, 2026 [Product]
Provide the API as well as the SDD (Spray Dried Dispersion)
[Indication]
1. Type 2 diabetes mellitus:To improve glycemic control in adults with type 2 diabetes mellitus.
2. For clinical research, now it can be used for Chronic weight management in adults.